Tryp Therapeutics Inc.

CSE: TRYP

Company Logo

Company Overview

Tryp Therapeutics is a clinical stage drug development company led by a management team with extensive drug development experience that is advancing transformative medicines with existing clinical data and known safety profiles for diseases with no effective first-line treatments. The company is building a diversified portfolio of product candidates targeting neuropsychiatric and oncology indications with high unmet medical needs.

Financial Highlights

$0

Revenue (ttm)

$0

Gross Profit (ttm)

-$0.02

Diluted EPS (ttm)

Management Team

Mr. Gregory M. McKee M.B.A., M.A., MBA
Exec. Chairman & CEO

Dr. James P. Gilligan
Pres & Chief Scientific Officer

Mr. Luke Hayes
Chief Financial Officer

Mr. Thomas D'Orazio B.Sc., M.B.A.
Chief Operating Officer

Ms. Joy Willis
Director of Investor Relations

Sign Up for Alerts

Receive an email alert every time a company announces a merger, capital raise or files for an IPO.

Company Profile

Website

Twitter

Presentation

Key Highlights

Market Capitalization
$14,670,922

Shares Outstanding
60,302,222

Shares Short (% of Float)
()

Insider Ownership
31%